-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baricitinib in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Baricitinib in Sicca Syndrome (Sjogren)Drug Details:Baricitinib (Olumiant) is an anti-inflammatory, immunomodulating and...
-
Company Profile
Evelo Biosciences Inc – Company Profile
Evelo Biosciences Inc (Evelo Biosciences) is a biotechnology company. It develops orally delivered product candidates for the treatment of inflammatory diseases and cancer. The company pipeline products include EDP1815 and EDP2939 among others. Its product EDP1815 treats mild to moderate psoriasis EDP2939 in psoriasis. Evelo Biosciences is also evaluating novel therapies to treat chronic diseases and cancer. It has its operations in the US and the UK. Evelo Biosciences is headquartered in Cambridge, Massachusetts, the US.
Add to Basket -
Product Insights
Net Present Value Model: EDP-1815
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EDP-1815 Drug Details EDP-1815 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EDP-2939
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EDP-2939 Drug Details EDP-2939 is under development for the treatment of skin inflammatory disease...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EDP-1815
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EDP-1815 Drug Details EDP-1815 is under development for the treatment of rheumatoid arthritis, skin...
-
Report Bundle
26% offTrends in Pharma – Report Bundle (4 Reports)
‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for...
-
Report Bundle
50% offInnovations in Pharma – Report Bundle (5 Reports)
Innovations in Pharma Bundle Report Overview The healthcare industry constantly demands innovation, improvement, accessibility, and affordability. The ‘Innovations in Pharma’ bundle highlights the emerging drug development technologies in providing quality healthcare services. Accessing the in-depth insight from the Innovations in Pharma bundle can help you: Make informed decisions about investments, partnerships, and product development Understand your competitors’ strengths and weaknesses, identify areas of opportunity, and develop strategies to stay ahead in the market Anticipate market changes and adjust your strategies accordingly...
-
Product Insights
Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared-up skin, itchiness, burning sensation, and swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections, and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. The Psoriasis pipeline market research report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug...
-
Thematic Analysis
Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research
Microbiome is the community of microorganisms such as fungi, bacteria, and viruses, and their genetic material existing in and on the human body. Although the primary site of aggregated microbes is in the gastrointestinal (GI) tract, populations of microorganisms are also found on the surface of the skin, in the upper and lower respiratory tract, and in the genitourinary tracts. Microbiome-targeting drugs aim to alter the microbial composition of the gut through the administration of live microbes (probiotics), or other...
-
Product Insights
Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atopic Dermatitis is an itchy inflammation of skin. Signs and symptoms of Atopic Dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender. The Atopic Dermatitis - Drugs In Development research report provides a comprehensive overview on the...